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In Brief
Sin-Chan et al. uncover a C19MC-LIN28A-MYCN super-enhancerdependent oncogenic circuit in embryonal tumors with multilayered rosettes (ETMRs). The circuit entraps an early neural lineage network to sustain embryonic epigenetic programming and is vulnerable to bromodomain inhibition, which promotes ETMR cell death.
INTRODUCTION
Embryonal brain tumors, the largest category of malignant brain tumors diagnosed in children 0-14 years of age, comprise a molecular and histologic spectrum of diseases that include medulloblastoma, rhabdoid tumors, and a more recently discovered tumor entity, embryonal tumors with multilayered rosettes (ETMRs), which were first identified based on recurrent amplification of the C19MC miRNA cluster on Chr19q13.41 (Li et al., 2009) . Subsequent studies revealed a spectrum of embryonal brain tumors previously categorized as distinct histologic entities that exhibited overlapping molecular features, which led to the categorization of C19MC-altered embryonal tumors as a single diagnostic entity in the revised 2016 World Health Organization CNS tumor classification (Louis et al., 2016) . ETMRs are now increasingly recognized as a distinctly aggressive brain tumor arising in infants and young children <4 years old with long-term survival of only 10%-20% (Korshunov et al., 2014; Li et al., 2009; Spence et al., 2014b) . To date, biological and therapeutic studies of this orphan disease has been significantly limited by a paucity of experimental and therapeutic models.
C19MC, which is the largest primate-specific miRNA cluster, encodes 54 miRNAs normally expressed in placental and germinal tissues (Bentwich et al., 2005; Bortolin-Cavaille et al., 2009 ). ETMRs exhibit histologic features reminiscent of early neural tube development and are transcriptionally enriched for genes with functions in early neural differentiation, including LIN28A, POU3F2, MEIS1/2, and SOX3 (Li et al., 2009; Pfister et al., 2009; Picard et al., 2012) , suggesting early neural progenitor origins. Significantly, ETMR RNA sequencing (RNA-seq) studies revealed fusion of C19MC to the promoter of TTYH1 (an embryonic chloride channel protein), and correlated C19MC miRNA expression with enrichment of an early neuralrestricted isoform of the de novo DNA methyltransferase, DNMT3B6 (Kleinman et al., 2014) . These observations, along with our previous demonstration that C19MC oncogenic miR-NAs (oncomiRs) modulates human neural stem cell (hNSC) growth and differentiation (Li et al., 2009) , suggests that C19MC may promote or maintain a primitive neural/embryonic epigenetic cell phenotype in ETMRs. However, oncogenic mechanisms and gene targets of C19MC remain elusive.
ETMR transcriptional signatures are enriched for high expression of LIN28A, a pluripotency factor and RNA-binding protein, which is implicated in neural development and in the pathogenesis of other advanced cancers (Viswanathan et al., 2009) . Notably, LIN28A is highly expressed in a small proportion of embryonal tumors with transcriptional and epigenetic features of ETMRs without evident C19MC alterations or expression, indicating an important role for this oncogene in ETMR pathogenesis 20 21 Figure 1 . Global Molecular Features of ETMRs (A) t-SNE visualization of unsupervised cluster analyses of 850k Illumina methylation array data from ETMRs (n = 80) and a reference dataset of childhood brain tumors and neuroblastoma (n = 643). (B) Circos plot of global methylation-based copy-number profiles in ETMRs. Regions of amplification/gains and losses are respectively highlighted in red and green. (C) High-resolution SNP copy-number profiles generated using allele-specific copy-number analysis of tumors in a representative ETMR with focal Chr19q13.42 amplification encompassing C19MC (red) and TTYH1 (blue) shown in zoomed-in view.
(D) Heatmap of NanoString (v.3) miRNA expression data from 21 ETMRs and 28 other PBTs showing the top 20% of miRNAs enriched in ETMRs; *q < 0.05. FDR, false discovery rate. See also Figure S1 and Table S1 . Neurogenesis   LIN28A  SALL4  MYCN   IGF2BP2   POU3F2  DNMT3B  DNMT3A  HDAC2  HDAC1  HDAC3  HDAC8  DICER1  TARBP2  PRKRA  ZCCHC11  MYC  CDKN2A  CDKN1A  CDKN2B  CDKN1B  RBL2  MAX  RB1  CASP8  ENDOG  BID  BAD  PRKCA  ZFP36  HSPA1A  UBC  YWHAB  NFIX  NFIC  NFIB   IGF2BP1   IGF2BP3 - (C) Schema of integrated differential RNA-seq analyses comparing hNSC6-5miR versus vector control cell lines (n = 2) and primary ETMRs (n = 22) versus other PBTs (n = 17); number of significantly up-, downregulated, and common C19MC responsive genes (FC > 1.2, <À1.2; *q < 0.05) are shown. Heatmap shows relative expression of select genes from the most highly ranked biological processes in ETMRs versus other PBTs identified using pathway analyses of 4,192 C19MC responsive genes; *q < 0.05. (D) Cytoscape visualization of biological processes (*q < 0.05) represented by the 4,192 genes identified in (C). Nodes represent related enriched gene sets, node size corresponds to total gene numbers. (E) qRT-PCR and western blot analyses of hNSC6, Daoy, UW228, and A664 cell lines with miR520g and 5miR expression, is shown relative to corresponding vector control lines.
(legend continued on next page) (Korshunov et al., 2014; Spence et al., 2014b) . In this study, we sought to define downstream targets and oncogenic mechanisms of C19MC, and to elucidate the functional relationship of C19MC and LIN28A in ETMR transformation.
RESULTS

Recurrent Chromosome 2 and 19 Copy-Number Alterations Are Hallmarks of ETMRs
The molecular landscape and pathogenesis of ETMRs remain largely unknown, as few of these tumor entities have been extensively characterized. To begin to elucidate mechanisms of ETMR pathogenesis, we examined 80 primary ETMRs using integrated global methylation, SNP, transcriptional, and miRNA profiling (Table S1 ). Methylation and transcriptional profiling showed ETMRs are distinct from other pediatric brain tumors (PBTs), notably embryonal brain tumors, including rhabdoid tumors, pineoblastoma and medulloblastoma (Louis et al., 2016) (Figure 1A) . Transcriptional analyses confirmed characteristic enrichment of stem cell maintenance and early neural/embryonic developmental pathways in ETMRs. Copy-number analyses using methylation and Omni SNP array data showed that Chr2 gains (77.5%) and focal Chr19 alterations (80%) centered on C19MC were the most frequent copy-number aberrations (CNA) and were concurrently present in 65% of ETMRs (Figures 1B and S1A-S1C). Detailed methylation/SNP (n = 80) and RNAseq (n = 22) analyses confirmed that C19MC was recurrently targeted by amplification/copy-number gains and fusions with TTYH1 ( Figure 1C ). Consistently, profiling of 565 miRNAs using NanoString analyses ( Figure 1D ; Table S1 ) showed that C19MC oncomiRs, and not the syntenic miR371-373 cluster (Li et al., 2009) , were exclusively upregulated in ETMRs, while expression of miR-15 and the let-7 tumor suppressor miRNAs were downregulated in ETMRs relative to other PBTs. Interestingly, the embryonic stem cell (ESC)-enriched 17-92 oncomiR cluster implicated in medulloblastoma (Murphy et al., 2013) , was upregulated in other PBTs, but only modestly expressed in ETMRs, underscoring a very specific causative role for C19MC oncomiRs in ETMRs.
C19MC oncomiRs Cooperatively Target Multiple Cell-Cycle Tumor Suppressors
We previously showed that individual C19MC miRNAs, miR520g and miR517c, can promote in vitro and in vivo transformation (Li et al., 2009) (Figures 2A and 2B) . These observations indicated that multiple C19MC oncomiRs may act cooperatively on gene targets to promote ETMR transformation.
To identify C19MC oncomiR targets relevant to primary ETMR biology, we first performed comparative RNA-seq analyses of hNSC6-5miR and corresponding vector controls to identify C19MC responsive genes and then integrated these data with differential RNA-seq analyses of ETMRs versus other PBTs to identify C19MC targets or effectors specifically enriched in ETMRs (detailed in Table S2 ). Differential analyses of hNSC6-5miRs versus control lines revealed 12,729 C19MC responsive genes (6,305 up-and 6,424 downregulated genes; n = 2; false discovery rate [FDR] < 0.05; fold change [FC] > 1.2, <À1.2), while analyses of primary ETMRs (n = 22) and other PBTs (n = 17) revealed 6,002 enriched genes (FDR < 0.05; FC > 1.2, <À1.2). Integration of the two datasets identified 4,192 common genes, of which 2,044 and 2,148 were, respectively, up-and downregulated in both hNSC6-5miR cells and ETMRs. Functional enrichment analyses of the 4,192 C19MC responsive genes revealed neural stem cell maintenance, epigenetic regulation, and miRNA processing genes as C19MC upregulated targets, while apoptosis, mRNA stability, and neurogenesis genes comprised C19MC downregulated targets ( Figures 2C and 2D ; Table S2 ).
In keeping with the rapidly proliferative nature of ETMRs and accelerated cell-cycle phenotypes in hNSC6-5miR cells, genes involved in cell-cycle regulation comprised one of the largest C19MC responsive hubs (12.5%; p = 1.32 3 10 À22 ; 347 upand 179 downregulated genes). As miRNAs predominantly negatively regulate gene expression, we focused on the 3 0 UTR sequences of the 179 downregulated cycle-cell genes to identify C19MC binding sites, using strict criteria detailed in methods. These analyses revealed that only 11/179 C19MC downregulated genes harbored multiple evolutionarily conserved C19MC miRNA binding sites in their 3 0 UTRs (Table S2 ). We applied H3K27Ac chromatin immunoprecipitation sequencing (ChIPseq) and assay for transposase-accessible chromatin using sequencing (ATAC-seq) data available for 5 ETMRs to assess the functional status of these loci in primary tumors and observed that only 5/11 loci, including AHR, CCND2, CDKN1A (p21), CDKN1B (p27), and RBL2, exhibited both active enhancer marks and open chromatin in a majority (>3/5) of ETMRs (Table  S2 ). Our analyses did not identify MYC or MAX, pRB pathway tumor suppressor genes (CDKN2A/B, CDKN2C, and RB1), TP53 or PTEN, which are frequently implicated in other brain tumors, (F) Summary of luciferase reporter assays in UW228 cells co-transfected with combinations of empty vector or miR520g/5miR expression plasmids, and wildtype (WT), mutated p21, or p27 3 0 UTR reporter constructs; 3 0 UTR 520g-t constructs served as miRNA target binding control. Luciferase activity was normalized to Renilla and vector control. (G) High-magnification image of miRNA in situ hybridization (ISH) and immuno-histochemical (IHC) analyses performed on sequential tissue sections of primary ETMR using fluorescence-labeled miR520g and scrambled control (scr) probes, and anti-p21, p27, and RBL2 antibodies. Scale bars, 100 mm. miRNA expression and tumor nuclei are respectively visualized in green and blue; corresponding regions in inset lower-magnification images are indicated by arrows. Scale bars, 20 mm. Ctrl indicates controls; data are presented as means ± SEM (n = 3); significance was determined by unpaired two-tailed Student's t test; *p < 0.05; mRNA expression is normalized to actin and tubulin served as western blot loading controls. See also Figure S2 and Table S2 . (H) Summary of luciferase reporter assays in UW228 cells co-transfected with empty vector, miR520g, 5miR expression constructs, and reporter constructs of wild-type (WT) or TTP 3 0 UTR with mutant C19MC binding sites; 520g-t constructs served as miRNA target binding control. Luciferase activity is normalized to Renilla and vector control.
(I) qRT-PCR and western blot analysis of A664 cells transfected with control or TTP expression construct.
(legend continued on next page) as C19MC targets. Notably, CDKN2A/2B, which were significantly downregulated in ETMRs ( Figure 2C ), lacked H3K27Ac marks and/or open chromatin in a majority of tumors, indicating that they were predominantly transcriptionally regulated.
As AHR and CCND2 have variably reported tumor suppressor activity, we focused on validating canonical cell-cycle tumor suppressors p21, p27, and RBL2 as direct C19MC targets (Figure S2G) . Consistent with cooperative effects of C19MC onco-miRs on gene targets, p21, p27, and RBL2 mRNA and protein were diminished by up to 2-fold in stable A664 and hNSC6 cell lines expressing 5miRs versus miR520g, and C19MC-mediated repression was conserved across different brain tumor cell lines (Daoy, UW228, PFSK) ( Figures 2E and S2H-S2J ). Importantly, expression of p14/16, RB1, TP53, and PTEN were unchanged in response to 5miR and anti-miR-mediated targeting of endogenous C19MC 5 miRs in ETMR2373-a C19MC amplified cell line, also rescued expressions of p21, p27, and RBL2, without effects on other cell-cycle regulators (Figures S2E, S2F, and S2K). Direct gene targeting by C19MC was confirmed using 3 0 UTR luciferase promoter assays, which showed that 5miR mediated significantly greater inhibition of p21 and p27 3 0 UTR activity than miR520g in UW228 cells, while repressive effects of both miR520g and 5miR were abrogated by mutations to C19MC binding sites on p21 and p27 3 0 UTRs ( Figures 2F and S2L ). Immuno-histochemical and miRNA in situ hybridization analyses confirmed that p21, p27, and RBL2 protein were absent in tumor cells with high C19MC oncomiR expression ( Figure 2G ), thus confirming these multiple cell-cycle tumor suppressors as relevant and direct targets of C19MC oncomiRs in primary ETMRs.
C19MC-LIN28A-MYCN Comprise a Feedforward Oncogenic Circuit
As ETMRs exhibit few other regions of focal copy-number alterations, we reasoned that C19MC may also drive ETMR growth via upregulation of oncogenes. Indeed, multiple oncogenes with functions in stem cell maintenance and neurogenesis were represented in the top 1% of the 2,044 genes (FDR = 7.58 3 10 À5 ) commonly upregulated in hNSC6-5miR and ETMRs (Figures 2C and 2D) . H3K27Ac ChIP-seq and ATAC-seq analyses revealed that 17 of the top 20 enriched genes, which included MYCN and LIN28A, exhibited active enhancer markers and open chromatin in a majority (3-5) of primary ETMRs (Table  S2 ). Western blot and qRT-PCR analyses showed that MYCN and LIN28A, but not the closely related MYC and LIN28B loci, were upregulated in hNSC6-5miR, while only MYCN was upregulated in hNSC6-miR520g cells ( Figures 3A and S3A ). Other genes enriched in ETMRs, including SALL4, CRABP1, SOX2/3, PROM1, and POU3F2, showed inconsistent or no changes with 5miR or miR520g expression. These findings, which suggested that MYCN and LIN28A were specific targets of C19MC, was further confirmed by analyses of stable A664-5miR cell lines ( Figures 3B and S3A ). As reciprocal LIN28B and MYCN regulation is observed in neuroblastoma, a pediatric peripheral nervous system tumor (Powers et al., 2016) , we investigated the possibility of a C19MC-LIN28A-MYCN regulatory circuit. Indeed, LIN28A knockdown in A664 and LIN28A expression in hNSC6 cells respectively resulted in up-and downregulation of MYCN, while MYC was unchanged ( Figures 3C, 3D , and S3A). Notably, we also observed that LIN28A and MYCN, but not LIN28B and MYC levels, correlated quantitatively with C19MC copy-number gains and amplification in primary tumors ( Figure 3E ), indicating that C19MC oncomiRs act cooperatively and specifically to drive the LIN28A-MYCN regulatory loop in ETMR.
To investigate C19MC-mediated regulation of LIN28A and MYCN, we examined the 3 0 UTRs of both oncogenes for potential target sequences of AU-rich element RNA-binding proteins (ARE-RBP), which function in mRNA decay. These analyses revealed 24 and 31 candidate ARE-RBPs, respectively, for LIN28A and MYCN; 3 of 5 ARE-RBPs predicted to target both oncogenes (TTP, KHSRP, hnRNPA1, and ELAVL1/2) harbored C19MC binding sites at 3 0 UTRs (Figures S3B and S3C; Table S3 ). Of these, only TTP (Tristetraprolin) was significantly downregulated in ETMR relative to other PBTs ( Figure 3F ), indicating that C19MC may act via TTP repression to upregulate LIN28A and MYCN. Indeed, stable 5miR expression robustly downregulated TTP in hNSC6 cells ( Figures 3G and S3D ), while mutation of C19MC binding sites on TTP 3 0 UTR rescued 5miR-mediated repression of TTP in luciferase reporter assays ( Figures 3H and S3E ). Furthermore, transient TTP expression in A664 cells led to diminished LIN28A and MYCN, but not LIN28B and MYC expression ( Figures  3I and S3D) . Interestingly, we observed that TTP was also upregulated with LIN28A knockdown in A664 as well as NCCIT, a germ cell tumor line with high endogenous LIN28A, and diminished in stable hNSC6-LIN28A cell lines, thus indicating that TTP also maps downstream of LIN28A. Consistently, TTP was downregulated in A664-5miR cells, which have high LIN28A expression ( Figures 3J, 3K , and S3D). Our aggregate findings suggest that multiple feedback loops drive a C19MC-LIN28A-MYCN oncogenic circuit in ETMRs.
LIN28A Modulates Epigenetic Effectors in ETMRs
The discovery of a C19MC-LIN28A-MYCN circuit together with high LIN28A expression in ETMRs implies a significant oncogenic role for LIN28A. Indeed, we observed that LIN28A expression and knockdown, respectively, enhanced and diminished viability of hNSC6 and A664 cells ( Figures 4A and 4B ). To investigate LIN28A oncogenic mechanisms and map ETMR-specific LIN28A targets, we performed and compared RNA-immunoprecipitation (RIP) coupled with RNA-seq analysis of A664 cells with RNA-seq profiles of A664 and primary ETMRs. Consistent with LIN28A functions in mRNA binding and stabilization , the largest category of LIN28A targets (49.4%) mapped to exonic and 3 0 UTR sequences ( Figure S4A ). RIP (J) qRT-PCR and western blot analysis of NCCIT, A664 cells treated with LIN28A, or control siRNA and hNSC6-LIN28A stable cell lines. (K) qRT-PCR and western blot analysis of stable A664-5miR and control cell lines. Schema shows C19MC-mediated regulation of LIN28A/MYCN via TTP inhibition. Validated and predicted regulation are shown by solid and dashed lines, respectively. In all cell line experiments, Ctrl indicates controls, data are presented as means ± SEM (n = 3); significance was determined by unpaired two-tailed Student's t test; *p < 0.05; mRNA expression is normalized to actin and tubulin served as western blot loading controls. See also Figure S3 and Table S3 . Other PBTs ETMR
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Relative expression (legend continued on next page) sequencing analyses identified 38,405 LIN28A binding sites (>2-fold enrichment; p < 0.05) corresponding to 7,146 unique target genes of which 805 were commonly enriched in A664 cells and ETMRs ( Figure 4C ). Specificity of LIN28A RIP was confirmed by qRT-PCR analyses of known LIN28A targets (CCNB1, LIN28A, and IGF2BP2/3) (Peng et al., 2011; Wilbert et al., 2012) , and unrelated genes (TUBB3 and RPLPO) ( Figure 4D ). Consistent with our previous work, functional enrichment analyses showed a substantial proportion of LIN28A targets mapped to cell growth, survival, and metabolism pathways (Figure 4E ; Table S4 ). Strikingly, epigenetic regulators including miRNA processing gene, DICER1 and de novo DNA methyltransferases (DNMT3A/3B), which exist in multiple isoforms during embryonic and fetal development, comprised the largest category (14.4%; 116/805 genes) of LIN28A-regulated transcripts enriched in ETMRs ( Figure S4B ). Although, LIN28A binding sites mapped to common 3 0 UTRs of DNMT3A and DNMT3B invariant exons 16/17, RNA-seq analyses indicated that DNMT3A2 and the enzymatically active DNMT3B6 isoform were most highly enriched in ETMRs relative to other PBTs ( Figures 4F and S4C-S4E ). Consistently, RIP qRT-PCR analyses showed LIN28A binding and enrichment of DICER1, DNMT3A2, and DNMT3B6, but not DNMT1, in A664 cells ( Figure 4G ), and that LIN28A knockdown diminished DNMT3A2, DNMT3B6, and DICER1 mRNA and protein expression, but had no effects on LIN28B and DNMT1 in A664 and NCCIT cells. Significantly, while DNMT3A2/3B6 and DICER1 mRNA and protein were also specifically upregulated in A664-5miR cells (Figures 4H, 4I , and S4F), treatment of ETMR2373 with anti-miRs targeting five C19MC miRs only resulted in downregulation of MYCN, LIN28A, and DNMT3A2/3B6 ( Figure S4G ). These collective findings suggest that the C19MC-LIN28A-MYCN oncogenic circuit acts in concert to enhance C19MC oncomiRs and embryonic DNMT3A2/B6 expression, and thus plays a critical role in promoting or maintaining the primitive, malignant epigenetic state that characterize ETMRs (Kleinman et al., 2014) .
Hijacked Super-Enhancers Amplify the C19MC-LIN28A-MYCN Oncogenic Circuit As enhancer hijacking by genomic alterations is increasingly implicated as an important mechanism in cancers Northcott et al., 2014) , we asked whether similar mechanisms may contribute to the C19MC-LIN28A-MYCN oncogenic circuit in ETMRs. To investigate these possibilities, we performed and integrated H3K27Ac ChIP-seq (nine tumors) and ATAC-seq (seven tumors) with copy-number and RNA-seq analyses of primary ETMRs to identify C19MC-, MYCN-, or LIN28A-associated enhancers that may be co-opted by genomic alterations. In addition, we used C3D (cross cell-type correlation) analysis, a tool to predict cis-regulatory interactions, on ETMR ATAC-seq data to determine whether these loci may be targeted by long-range DNA-DNA interactions.
Although previous limited RNA-seq studies suggested that high C19MC expression was driven by fusion of TTYH1 promoter and C19MC gene body, more detailed mapping of RNA-seq data from a larger cohort of 22 ETMRs revealed greater complexity to the TTYH1-C19MC fusion events (Table S5 ). Significantly, our analyses showed that TTYH1-C19MC fusion breakpoints flanked a broad genomic area of $790 kbs (Chr19: 54,142,428-54,932,953 bp) enriched for H3K4me1, H3K27me3, and H3K27ac marks and DNase I hypersensitive sites, indicating that TTYH1-C19MC gene fusions may juxtapose distinct putative TTYH1-and C19MC-associated enhancers to generate a unique hybrid super-enhancer ( Figure 5A ). H3K27Ac ChIP and ATACseq analyses of ETMRs confirmed that TTYH1-C19MC fusion breakpoints flanked a large chromatin accessible region that included a C19MC-associated enhancer element (Chr19: 54,162,824-54,167,441) $7 kb upstream of the first C19MC miRNA (miR-512-1) and 20.3 kb downstream of the genomic breakpoint (Chr19: 54,142,428), and a TTYH1-associated enhancer region (Chr19: 54,925,236-54,933,011) spanning a 7.7-kb region enriched for multiple transcription factor (TF) binding sites, indicating that it was a super-enhancer (Filippova et al., 1996; Malik et al., 2014) (Figures 5B and S5 ). Significantly, C3D analysis of ETMR ATAC-seq data revealed high probability (r = 0.84; p = 2.63 3 10 À10 ) of direct and specific interaction between the C19MC and TTYH1 super-enhancer regions ( Figure 5C ; Table  S5 ) and low probability of DNA-DNA interactions between flanking regions Chr19: 54, 929, 930, 435 and Chr19: 54, 960, 960, 945 . Collectively these findings point to a unique hybrid super-enhancer, created by the TTYH1-C19MC gene fusion ( Figure 5D ) that spans 32.73 kb, as a major driver of high C19MC oncomiR expression in ETMRs. Notably, the TTYH1-C19MC hybrid super-enhancer region exhibited multiple TF binding sites for MYC and MYC-binding partners, MAX and MAZ, further underscoring the importance of MYCN and a reciprocal C19MC-MYCN feedforward regulatory circuit in ETMRs.
In contrast, detailed SNP, methylation, and RNA-seq analyses did not reveal any focal LIN28A or MYCN genomic alterations in ETMRs. C3D analyses of ATAC-seq data predicted no significant DNA-DNA interactions targeting the LIN28A promoter in ETMRs. However, C3D/ATAC-seq analyses of ETMRs revealed a high probability of long-range interactions between the MYCN promoter (Chr2: 16,079,544-16,080,544) and five chromatin accessible regions on Chr2 (Chr2: 16, 124, 124, 602, 16, 154, 154, 821, 16, 397, 398, 207, 16, 404, 405, 254, 16, 511, 512, 136 ; r > 0.8; p < 1 3 10 À10 ) within 1.5 Mb upstream of MYCN ( Figure 6A ; Table  S6 ). ChIP-seq analyses of ETMRs showed that all five regions were enriched for H3K27Ac marks and spanned binding sites for multiple TFs, including CTCF, MYC, and MAX, indicating that they represented five distinct enhancers (e1-e5) ( Figures  6B and S6A) . Notably enhancers e1-e5, which correlated with high MYCN expression were only evident in ETMRs and hNSCs derived from 11-week-old fetal brain. These findings suggest that distinct long-range interactions between the MYCN promoter and early embryonic restricted e1-e5 enhancers contribute to the C19MC-LIN28A-MYCN oncogenic circuit.
(H and I) qRT-PCR (H) and western blot analysis (I) of NCCIT and A664 cells treated with LIN28A or control siRNA, and in stable A664-5miR and vector control cell lines. In all cell line experiments, controls are indicated by Ctrl, data are presented as means ± SEM (n = 3); significance was determined by unpaired two-tailed Student's t test; *p < 0.05, **p < 0.01; mRNA expression is normalized to actin and tubulin served as western blot loading controls. See also Figure S4 and Table S4 . (legend continued on next page) Interestingly, consistent with RNA-seq analyses of ETMRs and hNSCs ( Figure 6C ), a comparison of H3K27Ac enrichment patterns in ETMRs and hNSCs using the ENCODE/Epigenomic Roadmap database showed coordinated TTYH1, C19MC, LIN28A, MYCN, and DNMT3B6 active enhancer patterns only in ETMRs and 11-week-old fetal brain-derived hNSCs, and only partial overlap with enhancer patterns in other hNSCs and human placenta ( Figures 6D and S6B) . In contrast to DNMT3B6, the DNMT3A2 enhancer was present in a broader spectrum of normal and cancer cells. While ETMRs with C19MC alterations exhibited both the TTYH1-and C19MC-associated enhancers, only TTYH1-associated enhancers were evident in ETMRs without C19MC alterations. Taken together, our data suggest that unique TTYH1-C19MC hybrid super-enhancers and longrange MYCN-enhancer interactions amplify a C19MC-LIN28A-MYCN oncogenic circuit and drives expression of embryonic restricted DNMT3B6 to promote a primitive malignant epigenetic state in ETMRs.
An MYCN-Dependent Core Regulatory Circuit Represents a Therapeutic Vulnerability in ETMRs
Our collective analyses suggest that MYCN dysregulation is a critical component of the C19MC-driven oncogenic circuit in ETMRs.
As MYC has been implicated as a master TF, which drives superenhancer-dependent regulatory circuits and therapeutic vulnerabilities in cancer cells (Schuijers et al., 2018; Zeid et al., 2018) , we investigated if MYCN may act similarly in ETMRs. We applied the ROSE algorithm (Loven et al., 2013; Whyte et al., 2013) on H3K27Ac ChIP-seq data from 5 primary tumors and identified 1,330 super-enhancers, which were then subjected to a core regulatory circuitry (CRC) analysis to identify key TFs that drive autoregulatory loops (Saint-Andre et al., 2016). Of 190 candidate TFs (Table S7) , 18 emerged as core TFs that mapped to open chromatin regions, were highly expressed (fragments per kilobase million > 20) in ETMRs, and upregulated in hNSC6-5miR cells (Figure S7A ). These included MYCN and known MYC-binding partner, MAZ ( Figure 7A) . Notably, gene set enrichment analyses of the global super-enhancer functional network in ETMRs confirmed a predominance of MYCN/MAZ-regulated processes including embryonic and CNS development, cellular metabolism, differentiation, and survival ( Figure 7B ; Table S7 ), which are prominent features of ETMR transcriptional signatures (Li et al., 2009 ). Consistent with these analyses, MYCN and MAZ expression were significantly higher than that of MYC and its canonical partner MAX, in ETMRs and during early brain development, as indicated by BrainSpan data (Figures 7C and 7D) . These findings suggest that the C19MC-LIN28A oncogenic axis critically drives ETMR cell growth primarily via an MYCN/MAZ-mediated core transcriptional regulatory circuitry. To investigate this possibility, we treated A664 parental, A664-vector controls, and A664-5miR stable cell lines with JQ1S, an active isomer of JQ1, a bromodomain inhibitor that selectively inhibits super-enhancer-associated oncogenes such as MYC/MYCN. A664-5miR cells exhibited greatest sensitivity to JQ1S, with up to 50% dose-dependent reduction in cell viability as compared with parental or vector control cells (Figures 7E and S7B) . Notably, qRT-PCR and western blot analyses of cells treated with JQ1S and control inactive isomer JQ1R showed significantly greater downregulation of C19MC responsive core regulatory circuit effectors MYCN, MAZ, LIN28A, DNMT3B6/A2, and BRD2, in JQ1S-treated A664-5miR cells as compared with controls ( Figures 7F, S7C , and S7D). JQ1S treatment in ETMR2373 cells also robustly diminished expression of endogenous C19MC miRNAs, LIN28A and DNMT3B6, concomitant with increased PARP cleavage, without effects on LIN28B, DNMT1, and DNMT3A2 mRNA and protein expression ( Figures 7G and S7E) . These findings suggest that convergence of the C19MC-LIN28A and MYCN oncogenic circuits critically drive ETMR cell growth and represent a distinct therapeutic vulnerability in ETMRs (Figure 8 ).
DISCUSSION
C19MC oncomiRs are upregulated in a spectrum of cancers (Huang et al., 2008; Rajaram et al., 2007; Rippe et al., 2010) , but oncogenic genomic alterations are rare in most cancers. In contrast, our analyses revealed that a majority of ETMRs exhibit C19MC amplifications/gene fusions and few other recurrent CNAs, underscoring C19MC as a specific and major oncogenic driver in this disease. Indeed, our cumulative data suggest that C19MC is a powerful oncogene that acts to modulate tumor suppressors and oncogenes in ETMRs. We show that C19MC oncomiRs cooperatively target multiple cell-cycle regulators to promote proliferation in hNSC and ETMR cells in a manner similar to the orthologous murine miR290-295 cluster that inhibits ESC-cycle exit by targeting multiple checkpoint genes (Lichner et al., 2011; Wang et al., 2014) . Notably, our data show that C19MC acts via inhibition of TTP, an ARE binding tumor suppressor protein, to specifically upregulate the oncogenes LIN28A and MYCN, but not MYC, which is regulated by TTP in other cancers Lee et al., 2013) . Interestingly, our data show that LIN28A also acts as a negative and positive regulator for TTP and MYCN, respectively, thus indicating a C19MC-LIN28A-MYCN oncogenic circuit that is driven by multiple convergent mechanisms in ETMRs. Although ETMRs also have high LIN28B expression, our studies show the C19MC/ TTP axis only targets LIN28A, indicating that LIN28B is regulated by alternate mechanisms. Consistent with our previous studies that implicated a LIN28A-let-7 axis in ETMR cell growth (Spence et al., 2014a (Spence et al., , 2014b , we observed very limited expression of let-7 in ETMRs. Whether let-7 contributes to LIN28A-MYCN See also Figure S5 and See also Figure S6 and Table S6 . (legend continued on next page) regulation in ETMRs, as reported in other cancers (Molenaar et al., 2012; Powers et al., 2016) , remains to be studied. In addition to promoting cell proliferation, our RIP studies suggest that LIN28A plays a major role in ETMR epigenetic programming via direct binding and regulation of mRNAs encoding epigenetic regulators including DNMT3A and DNMT3B, which have isoform-restricted expression during brain development. While DNMT3A2, which functions in genomic imprinting and germ cell development (Ma et al., 2015; Nimura et al., 2006) , is expressed in up to 16-week-old fetal brain, DNMT3B6 expression is highest in <8-week-old fetal brain. Interestingly, RNAseq data suggest that DNMT3A2, as well as DNMT3B6, which is the only enzymatically active isoform expressed in ETMRs, are almost exclusively expressed in ETMRs and not other PBTs, underscoring the very distinct and primitive epigenetic features of this disease. Both DNMT3A2 and DNMT3B6 are detected in ETMRs with and without C19MC copy-number alterations (data not shown), indicating that these isoforms may reflect a common epigenetic cell state in these tumors that is (G) miRNA qRT-PCR and western blot analyses of ETMR2373 cell lines treated with active JQ1S or inactive isomer JQ1R for 24 h. In all cell line experiments, controls are indicated by Ctrl, data are presented as means ± SEM (n = 3); Significance was determined by unpaired two-tailed Student's t test; *p < 0.05; mRNA and miRNA expression are respectively normalized to actin, RNU6B, tubulin served as western blot loading controls. See also Figure S7 and Table S7 . In keeping with early embryonic epigenetic features of ETMRs, we observed that exogenous C19MC have limited transforming activity in postnatal murine neural precursors (our unpublished data). Consistent with our previous study that linked C19MC expression with Sonic hedgehog (SHH) and WNT developmental signaling in ETMRs (Li et al., 2009; Picard et al., 2012) , we observed enrichment of multiple SHH and WNT pathway components, including GLI2 and AXIN2, in RIP studies indicating that C19MC may act via LIN28A to modulate these lineage-determining pathways. Interestingly embryonal tumors with histological and transcriptional features resembling human ETMRs have been reported by concurrent activation of SHH and WNT signaling in murine neural precursors (Neumann et al., 2017) . However, these murine tumors lacked characteristic LIN28A expression patterns seen in human tumors, indicating that alternative strategies may be needed to model ETMRs.
Super-enhancers are clusters of enhancers that determine cell-type-specific transcriptional signatures by regulating master TFs or lineage-associated miRNAs, including miR290-295, which define cellular identity and origins (Suzuki et al., 2017; Whyte et al., 2013) . Super-enhancers have also been increasingly implicated in activation of driver oncogenes, and they have been shown to confer distinct tumor cell dependencies and sensitivities to drugs that target super-enhancer components (Loven et al., 2013) . Our studies revealed that super-enhancers co-opted by TTYH1-C19MC gene fusions, and long-range MYCN promoter-enhancer interactions, were restricted to ETMRs and powerfully amplify a C19MC-LIN28A-MYCN oncogenic circuit. Notably, our enhancer mapping studies suggest that the functional status of TTYH1, C19MC, LIN28A, MYCN, and DNMT3B6, which comprise the core components of the C19MC-LIN28A-MYCN oncogenic circuit, most closely mirrors that of early neural stem cells from $11-weekold fetal brain. Consistent with a super-enhancer-driven C19MC-MYCN dependency in ETMRs, we observed transient MYCN knockdown induced growth arrest in A664 cells (data not shown), while bromodomain inhibitor JQ1 induced death in A664 and A664-5miR cells. Notably, JQ1 treatment downregulated only key components of the oncogenic lineage circuit including MYCN, LIN28A, DNMT3B6, but not LIN28B, DNMT3A2, or DNMT1, which was mirrored by anti-miR-mediated targeting of endogenous C19MC in ETMR2373 cells. Thus, we propose that C19MC drives a distinct lineage-associated dependency and vulnerability in ETMRs.
Our collective findings in this study highlight ETMR as a developmental cancer arising in embryonic neural progenitors that is driven by hijacked lineage-specific signaling pathways. We identify cellular proliferation and embryonic epigenetic programming as key features of this disease, which is sustained by a unique potent super-enhancer-dependent oncogenic circuit vulnerable to bromodomain inhibition. Our data suggest that pharmacologic agents targeting BET/bromodomains may represent promising therapeutics for this recalcitrant orphan cancer.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
Immuno-Histochemical (IHC) and Western Blotting Analysis
For IHC studies, a heat-induced antigen retrieval process was used, followed by blocking of endogenous peroxidase and biotin. Primary antibodies against p21 (Cell signaling, Cat#2947), p27 (BD Biosciences, Cat#610242) and RBL2 (Sigma Aldrich, Cat#HPA019703) were used. Antibody reactivity was visualized using VectaStain ABC detection kit (Vector Laboratories, Cat#PK-4000). For western blot analyses, whole cell lysates were prepared using cytosol lysis buffer and probed with various antibodies using standard protocols. (For antibodies, see Key Resources Table) . Immunoreactivity was detected using secondary anti-species horseradish peroxidase-conjugated antibodies (GE Healthcare, #NAV934/931) and Chemi-luminescence Reagent Plus (PerkinElmer, Cat#NEL103001EA).
miRNA In Situ Hybridization Analysis miRNA in situ hybridization (ISH) was performed using Alexa 488 (Thermo Fisher, Cat# A20181) coupled miR520g or scrambled probes (Qiagen) on sequentially sectioned formalin fixed paraffin embedded primary ETMR using miRCURY LNA miRNA ISH Optimization Kit (Qiagen, Cat#339451). Signals were amplified using Tyramide Signal Amplification kit (Thermo Scientific, Cat#B40953). Fluorescence was detected using the Pannoramic 250 Flash series digital scanner. To compare miRNA amplified tumor cells with protein levels of p21, p27 and RBL2, we performed IHC analysis on sequentially sectioned tumors of the same ETMR and located the same geographical region on the tumor for all analyses.
Luciferase Reporter Assays
To assess direct effects of 5miR on target genes, 3'UTR constructs of p21, p27 and TTP from corresponding full lengths genes (SPARC, Hospital for Sick Children; Canada) were sub-cloned into a pmirGLO Dual-Luciferase miRNA target expression vector (Promega, Cat#E1330). C19MC binding sites were identified using miRNA target prediction algorithms (Targetscan, miRanda and DIANA -see Table S2 ) and seed sequences mutated using QuiKChange Site directed mutagenesis kit (Stratagene, Cat#200524). For luciferase assays, stable UW228-pcDH/miR520g/5miR cells were seeded at 0.3E5/well in triplicate in a 12-well plate and transfected with empty pmiRGLO, wild-type, mutated target gene 3'UTR or a control miR520g complementary (520-t) vector. Cells were harvested 48 hours post-transfection using Dual-Luciferase Reporter Assay System (Promega, Cat#E1910) and luciferase activity measured using the Lumat LB 9507 tube luminometer. Luciferase activity was normalized to empty pmiRGLO vector and Renilla. All assays were performed n=3.
Identification of C19MC Gene Targets
To identify which of the 179 downregulated cell cycle genes may be targeted by the 5 major classes of C19MC miRNA families (miR-520, 519, 517a/c and 512), we utilized three distinct miRNA target predictions algorithms including TargetScan, miRanda and DIANA. Our strict criteria included a) whether the 3'UTR of these genes contained R2 C19MC binding sites, b) whether the same binding site locations were conserved across all three algorithms and c) whether the sites were evolutionarily conserved. Based on these criteria, 11/179 genes emerged as C19MC candidate targets. H3K27Ac and ATACseq data were used to validate the functional status of the 11 candidate targets in primary ETMR, which revealed only 5 genes (p21, p27, RBL2, CCND2 and AHR) that exhibited active enhancers and open chromatin, indicating these genes were transcriptionally active in ETMRs.
RNA Binding Protein Predictions
The RNA Binding Protein Data Base software (http://rbpdb.ccbr.utoronto.ca/) (Cook et al., 2011) was used to predict RNA binding protein targeted to the 3'UTR of LIN28A, MYCN, LIN28B and MYC.
Unsupervised Analysis of ETMR with Other Paediatric Brain Tumor For unsupervised analyses of ETMR and other PBTs, raw idats or normalized beta matrix values of methylation data for medulloblastoma , atypical teratoid/rhabdoid tumor (ATRT) (Johann et al., 2016; Torchia et al., 2016) , neuroblastoma (Gomez et al., 2015) , pilocytic astrocytoma (Lambert et al., 2013) , ependymoma (Mack et al., 2014; Sturm et al., 2016) , high grade glioma (Sturm et al., 2012 , pineoblastoma were downloaded from GEO and combined with in-house samples in the pipeline described above. Principal component analysis (PCA) was performed using R package stats (v3.3.3) and the top 50 principle component used for tSNE analysis with the Rtsne package (v0.13). 5-50 perplexity were tested to find the optimal settings. Other non-default settings: pca=F, max_iter=5000, theta=0. Each of the aforementioned tumor group form distinct entities with no batch effect by material type and processing date was observed with distinct clustering of samples according to tumor subtype.
Genome Wide Copy Number Alteration Analysis with Methylation and SNP Arrays
Genome-wide copy number analyses were performed using SNP (n=33) and methylation array data (n=77). For SNP array analyses, the Illumina OmniQuad array platform was used. Probe fluorescence intensity normalization and transformation was performed using Illumina Genome Studio (v. 2011.1 Genotyping Module 1.9.4) and represented as LogR ratio (Log2[R experiment /R controlset ]) and B-allele frequency (BAF) using hg19 human reference genome. ASCAT (Allele Specific Copy Number Analysis of Tumors) was performed to assess tumor purity and ploidy using its control-free analysis function at default parameters. Methylation array data was analysed using the R package conumee for the 450k array and EPIC array (v 1.2.0 and 1.8.0 respectively) using default settings. For both methylation and SNP array data, tumor probe level LogR and segmented profiles were visualize using the R package Gviz (version 1.18.2). Recurrent focal and arm-level structural alteration was analyzed using GISTIC2 (v03172017). At least half of the chromosome arm must be affected to be considered as a broad event for arm-level structural alteration analysis. For focal alterations, -0.3 and 0.3 deletion and gain threshold respectively to identify driver events with the HLA region Chr6:28477797-33448354 excluded. For both type of analysis, significant alterations were evaluated based on Benjamin-Hochberg false discovery rate corrected p values for each marker from comparing the score at each locus to background score generated by random permutation of marker location with q % 0.01.
Normalized and log2-transformed copy number measurements were imported and analysed using CopyNumber package pipeline (Nilsen et al., 2012) to identify segments with similar copy number. Binned segmentation results of conumee output from methylation arrays from all primary ETMR (N=77) were used to generate a composite copy number plot. Average Log2 levels were calculated across overlapping segments with noise removal from HLA region and end of chromosome arm using an in-house script. The results were plotted using Circos (v0.69).
Processing of miRNA Nanostring Data
Total RNA (100ng) from 21 ETMRs with C19MC structural alterations and 28 other PBTs was prepared with nCounter miRNA Sample Prep Kit according to standard protocol. miRNA expression profiling was conducted with human v1, v2, or v3 miRNA panel on nCounter miRNA expression platform (NanoString Technologies, Seattle, WA) according to manufacturer's protocol. Signal normalization was done using nSolver Analysis and batch corrected using ComBat (Johnson et al., 2007) . 565 miRNAs overlapped between all three versions and was used for further analyses. Fold change and supervised t-test with FDR correction was calculated between the ETMRs and other PBTs.
RNAseq Analyses and Fusion Calling
RNAseq of tumor and cell lines were performed at the Princess Margaret Genomics Centre (Toronto, Ontario). RNA was prepared using either the IlluminaTruSeq RNA sample preparation kit for poly-adenylated mRNA or Illumina RiboZero Stranded library preparation kit for total RNA with an average of 97.64 million and 92.13 million paired-end reads per sample respectively. Adapter sequences were trimmed using Cutadapt (v 1.10) and aligned to human reference genome hg19 using TopHat (v2.1.0). Gene expression values were represented as FPKM values generated from RNAseq alignments using cuffquant and cuffnorm programs within the Cufflinks RNAseq assembly suit (v2.2.1) (Trapnell et al., 2012) with geometric library normalization.
TTYH1-C19MC gene fusion break points were assessed based on concordance of and SNP array/Methylation array copy number analysis. RNAseq fusions breakpoints were called using TopHat-Fusion (v2.1.0). Paired-end reads were aligned to a GRCh19 reference genome using the following parameters specifically for finding fusion transcripts: -fusion-anchor-length 15 -fusion-min-dist 10000 -segment-length 50 -mate-inner-dist 0 -mate-std-dev 80. False positive from TopHat-Fusion were further assessed using TopHat-fusion-post by aligning the sequences flanking fusion junctions against BLAST (Basic Local Alignment Search Tool) databases (human genomic, other genomic and nt) and also manual inspection with Integrative Genomics Viewer (IGV) (v2.3.72).
Methylation and RNAseq Public Data
Additional methylation (GSE49377, GSE54719, GSE70460, GSE75153, GSE73801, EGAS00001000506) and RNAseq (SRP032476) data were downloaded from public resources.
H3K27Ac ChIPseq Sample Preparation and Analysis
Snap-frozen primary tissues were prepared for H3K27Ac ChIPseq analyses according to previously published methods (Mack et al., 2018) . Briefly, formaldehyde cross-linked chromatin from 1E6 cells or 5 mg of snap frozen tumor samples were fragmented via water
